The interactions of glycosaminoglycans (GAGs) with proteins underlie a wide range of important biological processes. However, the study of such binding reactions has been hampered by the lack of a simple frontline analysis technique. Previously, we have reported that cold plasma polymerization can be used to coat microtiter plate surfaces with allyl amine to which GAGs (e.g., heparin) can be noncovalently immobilized retaining their ability to interact with proteins. Here, we have assessed the capabilities of surface coats derived from different ratios of allyl amine and octadiene (100:0 to 0:100) to support the binding of diverse GAGs (e.g., chondroitin-4-sulfate, dermatan sulfate, heparin preparations, and hyaluronan) in a functionally active state. The Link module from TSG-6 was used as a probe to determine the level of functional binding because of its broad (and unique) specificity for both sulfated and nonsulfated GAGs. All of the GAGs tested could bind this domain following their immobilization, although there were clear differences in their protein-binding activities depending on the surface chemistry to which they were adsorbed. On the basis of these experiments, 100% allyl amine was chosen for the generation of a microtiter plate-based "sugar array"; X-ray photoelectron spectroscopy revealed that similar relative amounts of chondroitin-4-sulfate, dermatan sulfate, and heparin (including two selectively de-sulfated derivatives) were immobilized onto this surface. Analysis of four unrelated proteins (i.e., TSG-6, complement factor H, fibrillin-1, and versican) illustrated the utility of this array to determine the GAG-binding profile and specificity for a particular target protein.
Introduction
Glycosaminoglycans (GAGs), unbranched polysaccharides found ubiquitously on the cell surface and in the extracellular matrix, are crucial for numerous biological processes including blood clotting (de Agostini 2006; Gray et al. 2008) , tissue organization (Evanko et al. 2007; Cain et al. 2008; Galtry et al. 2008) , the immune response (Kuschert et al. 1999; Mahoney et al. 2005; Clark et al. 2006; Taylor and Gallo 2006; Banerji et al. 2007; Prosser et al. 2007 ), reproduction (de Agostini 2006; Scarchilli et al. 2007) , and development (Camenisch et al. 2000; Lin 2004; Bao et al. 2005; Johnson et al. 2007 ). Such processes occur as a direct consequence of the interactions of GAGs with a wide variety of proteins, e.g., proteolytic enzymes, growth factors, and chemokines. The ability to identify and characterize these binding reactions is therefore of key importance in biological research. To date, such studies have been hampered by the lack of a simple method for the analysis and preliminary characterization of protein-GAG interactions (Mahoney et al. 2004; Wisniewski et al. 2005) .
The lack of adherence of GAGs, such as heparin, to plastic surfaces (e.g., microtiter plates), restricts the use of ELISAlike assays in the investigation of protein-GAG interactions (Mahoney et al. 2004; Robinson et al. 2008) . One previous method adopted to address this issue has been the covalent coupling of GAGs (e.g., heparin, heparan sulfate, and chondroitin sulfate) with bovine serum albumin (BSA) in order to facilitate their surface immobilization (Najjam et al. 1997; Hasan et al. 1999; Nishioka et al. 2007 ). This requires the bespoke production of GAG-BSA complexes or the use of commercial preparations (e.g., heparin-BSA) where there is no control over the composition of the GAG attached. Another approach has been to determine the binding of biotinylated GAGs to immobilized proteins (Parkar and Day 1997; Nadesalingam et al. 2003; Mahoney et al. 2005; Harris et al. 2008) . However, the methods of biotinylation that are commonly used, i.e., the attachment of biotin molecules either to the GAG carboxylate (Yang et al. 1995; Parkar and Day 1997; Boucas et al. 2008) or amino (Nadesalingam et al. 2003; Mahoney et al. 2005; Harris et al. 2008) groups, have different levels of efficiency and can alter the functional properties of the GAG (Yang et al. 1995; Saito et al. 2005; Boucas et al. 2008) . For example, the protein-binding capacity of dermatan sulfate has been observed to be higher when biotin was attached to the free amino groups (which are rare in sulfated GAGs) as compared to the uronic acid (Saito et al. 2005) . However, other studies have shown that labeling of carboxylate moieties works efficiently for hyaluronan while giving poor results for heparin (Yang et al. 1995) . These studies highlight the fact that the optimal method of biotinylation may be GAG specific such that careful optimization of labeling conditions is necessary for each individual GAG-protein interaction. Additionally, immobilization of proteins on microtiter plates can lead to loss of function through either steric hindrance or via conformational perturbation (Marson et al. 2005) .
We have shown previously that cold plasma polymerization can be used to coat microtiter plates with allyl amine, generating a surface that allows the noncovalent immobilization of the GAGs heparin, heparan sulfate, and dermatan sulfate in a functionally active (i.e., protein binding) state (Mahoney et al. 2004 Clark et al. 2006) ; this method negates the need for covalent labeling/coupling of the GAG. More recently, we have demonstrated that related surfaces (made from different ratios of allyl amine and octadiene monomers) can be used to fabricate a concentration gradient of functional heparin (Robinson et al. 2008 ). Importantly, a surface chemistry was identified upon which an optimal amount of functional low-molecularweight (LMW) heparin could be immobilized so as to give rise to maximum protein binding; this "sweet spot" did not correlate with the conditions where the maximum amount of heparin was bound to the surface.
Here, we have used this observation as the basis for a comprehensive study of the protein-binding properties of a diverse group of GAGs (i.e., LMW and unfractionated heparin (UFH), selectively desulfated heparins, chondroitin-4-sulfate, dermatan sulfate, and hyaluronan) following their noncovalent immobilization upon a range of surface chemistries (i.e., 100:0 to 0:100% allyl amine:octadiene). This has allowed the development of a simple microtiter plate-based GAG array that has significant utility as a frontline technique in the determination of the GAG-binding profile and specificity of a target protein; e.g., establishing the ability of the protein to interact with sulfated GAGs and the nonsulfated polysaccharide hyaluronan. In this regard, we have used the array to determine the GAG-binding properties of four unrelated proteins to determine and illustrate the utility of this methodology.
Results

Immobilization of functional GAGs on a range of allyl amine:octadiene surfaces
Initially assays were performed to study the protein-binding properties of UFH immobilized (in PBS) on the different surface chemistries (100:0, 90:10, 80:20, 70:30, 60:40, 40:60, 20 :80, 0:100% allyl amine:octadiene) at a range of concentrations (see Material and methods). The biological activity of the surfacebound GAG was determined using the Link module domain from human TSG-6 (termed Link_TSG6), a known heparinbinding protein . This domain, which also interacts with the GAGs heparan sulfate, chondroitin-4-sulfate, dermatan sulfate, and hyaluronan (Parkar and Day 1997; Mahoney et al. 2004 Mahoney et al. , 2005 Milner et al. 2006) , was monobiotinylated (denoted as bA-Link_TSG6) allowing its detection as described previously (Parkar and Day 1997; Mahoney et al. 2004 Mahoney et al. , 2005 Robinson et al. 2008) . As shown in Figure 1 , the amount of functional heparin present on the microtiter plate surface (i.e., as determined from the level of bA-Link_TSG6 binding) was highly dependent on the nature of the surface chemistry. In all cases, there was an increase in protein binding with increasing concentration of immobilized GAG (i.e., the protein binding was dose dependent), but the absolute amount of functional heparin detected differed greatly. For example, there was only a low level of protein binding when the heparin was coated onto 0% and 20% allyl amine (i.e., with 100 and 80% octadiene, respectively), whereas, close to maximal functional, heparin was seen on the surfaces coated with 60-90% allyl amine. In general, there was a higher level of protein binding to UFH adsorbed onto the higher ratios of allyl amine:octadiene, with the exception of the 100% allyl amine condition that has an intermediate protein-binding capacity. This relationship can be seen clearly in Figure 2A , which compares the binding of the bA-Link_TSG6 protein to UFH and LMW heparin immobilized (at 5 μg/well) on the different surface chemistries. From this it is apparent that these two preparations of heparin behave very similarly.
Given that the Link_TSG6 domain recognizes a wide range of GAGs, we used this protein to assess the functional activities of chondroitin-4-sulfate, dermatan sulfate, and hyaluronan immobilized on the various plasma-polymerized surfaces (Figure 2 ). Whereas UFH and LMW heparin displayed little or no protein binding when immobilized on 0% and 20% allyl amine (previously shown for LMW heparin to be due to the low level of GAG that becomes bound to these surfaces (Robinson et al. 2008) ), chondroitin-4-sulfate, dermatan sulfate, and hyaluronan all interacted with the bA-Link_TSG6 protein under these conditions. In the case of the 0% allyl amine (100% octadiene) surface, this was shown to be largely due to the interaction of the GAGs with the octadiene polymer since a lower Sugar array for glycosaminoglycan-protein interactions Fig. 2 . The protein-binding activities of various GAGs immobilized on different surface chemistries. Microtiter plates were coated with plasma polymers of allyl amine as described in Figure 1 . GAGs (A: UFH ( ) and LMW (᭺) heparin; B: chondroitin-4-sulfate (᭝), dermatan sulfate (᭜), and hyaluronan (᭞)) were incubated (5 μg/well) with the coated wells and the binding capabilities of immobilized GAG determined using bA-Link_TSG6; results for LMW heparin have been reported previously (Robinson et al. 2008) . For easier comparison, the data were normalized against the value for maximum protein binding seen for a particular GAG (i.e., on the optimal surface chemistry). These data are plotted as % maximum protein binding ± SEM (n = 8), corrected against blank wells (i.e., with no GAG). The absolute maximum A 405 nm values obtained for UFH (on 70% allyl amine), LMW heparin (90%), chondroitin-4-sulfate (100%), dermatan sulfate (90%), and hyaluronan (100%) were 1.19, 1.05, 0.82, 1.55, 0.54, respectively. level of protein binding was seen when they were incubated with identical plates that had not been plasma polymerized (Figure 3 ). Dermatan sulfate displayed a medium to high level of protein binding on all of the surface chemistries tested ( Figure 2B ); the maximum binding seen for this GAG (i.e., on 90% allyl amine) was ∼1.3 times higher than that for UFH. In contrast, chondroitin-4-sulfate and hyaluronan displayed reasonable levels of functional activity when immobilized on either low or high percentages of allyl amine with optimal protein binding associated with the 100% surface; the maximal binding of Functional GAG binding to untreated surfaces compared to those coated with 100% octadiene. Microtitre plates were plasma polymerized with 100% octadiene or left untreated. These surfaces were incubated (at 5 μg/well) with various GAGs (unfractionated heparin (UFH), dermatan sulfate (DS), chondroitin-4-sulfate (C4S), and hyaluronan (HA)) and their protein-binding capabilities determined using bA-Link_TSG6. Data for the coated (black bars) and uncoated (white bars) surfaces are plotted as mean absorbance at A 405 nm ± SEM (n = 8), corrected against blank wells (i.e., with no GAG).
bA-Link_TSG6 to these GAGs was 0.69-and 0.46-fold lower, respectively, than that for UFH. As can be seen from Figure 2B, chondroitin-4-sulfate and hyaluronan had relatively poor protein-binding capabilities when they were immobilized on 70 or 80% allyl amine, indicating that the mechanisms underlying the adsorption of these GAGs may be different on low and high percentages of allyl amine. Overall, these studies demonstrate that all of the GAGs analyzed can be immobilized on plasma-polymerized surfaces and retain their ability to interact with protein. In this regard, the ability of the various surfaces to support functional GAG binding is clearly GAG specific.
Design and setup of a microtiter plate-based sugar array
The above-mentioned studies identified two surface chemistries, namely 100% and 90% allyl amine that are able to support high levels of bA-Link_TSG6 binding to all of the GAGs tested (i.e., heparin, chondroitin-4-sulfate, dermatan sulfate, and hyaluronan). This indicates that there is an efficient immobilization of these GAGs in a functional form and, thus, provides the basis for the design of a microtiter plate-based sugar array that can be used to profile the specificity of GAG-protein interactions. Microtiter plates plasma polymerized with 100% allyl amine were chosen for the development of the sugar array in combination with the GAGs investigated above. Our previous binding studies with complement factor H demonstrated that selectively desulfated heparin preparations, which have lower levels of sulfation and can be used as models of the GAG heparan sulfate, could also be immobilized on the 100% allyl amine surface in a functionally active form (Clark et al. 2006 ); the 
and N-desulfated/re-N-acetylated (N-deS/R)) revealing that these GAG preparations were being immobilized on the plate surface.
Additional experiments with these same heparin preparations included here indicated that Link_TSG6 binding was more sensitive to changes in sulfation (Figure 4) . Furthermore, selective removal of different types of sulfate group caused differential effects on the interaction between Link_TSG6 and heparin. For example, N-deS/R (i.e., the removal of the N-sulfate and its replacement with an acetate moiety) retained the highest level of Link_TSG6 binding, whereas, there was a much lower binding to 2-O-deS (compared to the "parental" UFH from which these were made). Therefore, these two representative desulfated heparin preparations (N-deS/R and 2-O-deS) were also included in the sugar array, i.e., as defined models of heparan sulfate. From Figure 4 , it can also be seen that the combined removal of all 2-O-and 6-O-sulfates effectively abolished Link_TSG6 binding. Overall, these data suggest that the 2-O and 6-O-sulfates have a more important role in mediating the binding of heparin to the TSG-6 Link module than the N-sulfate groups. As such it is apparent that this type of assay can provide useful information on the molecular basis of protein-heparin/heparan sulfate interactions.
Thus, in total, seven different GAG preparations were used to generate a prototype sugar array (i.e., UFH, LMW heparin, chondroitin-4-sulfate, dermatan sulfate, hyaluronan, 2-O-deS heparin, and N-deS/R heparin). In order to provide an indication on whether the binding of a particular protein to an immobilized GAG is dose dependent, two concentrations of each GAG (0.2 and 2 μg/well) were included in the array. These concentrations were chosen since 2 μg/well gave rise to maximum bA-Link_TSG6 binding for UFH (and the other sulfated GAGs tested; data not shown), whilst binding to the lower concentration of GAG was in all cases suboptimal (see Figure 1) . X-ray photoelectron spectroscopy (XPS) revealed (from the S2p sulfur signal; Figure 5A and B) that at both these concentrations, once the relative sulfation levels of each of the GAGs were accounted for, similar absolute amounts of the sulfated GAGs were immobilized on the allyl amine microtiter plate surface ( Figure 5B and D) . Thus, there does not appear to be any major effect of the level of GAG sulfation on the amount of GAG immobilized on the allyl amine-coated surface. For example, from Figure 5 (B and D) it can be seen that there is a similar amount of UFH, N-deS/R, and DS bound to the plate surface, where these GAGs have widely different levels of sulfation (i.e., approximately 2.5, 1.5, and 1 sulfates, respectively, per disaccharide). In the case of 2-O-deS (1.5 sulfates per disaccharide), there does appear to be somewhat less of this heparin immobilized (at 0.2 μg/well; Figure 5B ) compared to the other GAGs. The most likely explanation for this is that 2-O-deS heparin is of a lower molecular weight (3.7 kDa) than the other GAG preparations used in the XPS study (all ≥10.4 kDa; as determined by size exclusion chromatography (Mulloy 2002) ); a consequence of its harsh method of preparation (Jaseja et al. 1989) . In this regard, we showed previously that immobilization of low-molecularweight preparations of heparin (e.g., dp10 oligomers; ∼3 kDa) onto allyl amine at low concentrations (such as 0.2 μg/well) supported less protein binding than higher molecular weight heparins (Mahoney et al. 2004 ). However, as can be seen from Figure 5D , the amount of 2-O-deS heparin that becomes bound to the allyl amine-coated surface is equivalent to that of the other sulfated GAGs, when these are immobilized from the higher concentration (i.e., at 2 μg/well). The level of immobilized hyaluronan could not be quantified by XPS from the S2p signal because this GAG does not contain sulfate groups. However, C1s spectra (data not shown) indicated the introduction of peak shifts at higher binding energies (i.e., COO − ) consistent with the successful immobilization of the GAG. Therefore, for the sulfated GAGs, at least, any variability in the level of binding by a given protein to the panel of GAGs should be considered to largely reflect its differential binding specificities/affinities.
The XPS experiments described above also indicated that the relative amounts of the various GAGs that become immobilized on the allyl amine surface are similar at both the 0.2 μg/well and 2.0 μg/well coating concentrations ( Figure 5A and C). To further investigate this, 35 S-labeled heparin was used to determine the absolute amount of heparin that becomes bound per well and whether this is dependent on the concentration of the coating solution. As shown in Figure 6 , a similar level of heparin (∼100 ng/well) becomes immobilized on the 100% allyl amine plates when incubated with the wells at concentrations between 0.1 and 2 μg/well (i.e., including the two concentrations of GAG chosen for the array); a higher level of heparin binding (∼200 ng/well) was only observed at the highest coating concentration tested (9.5 μg/well). From the data presented in Figure 1 , it can be seen that heparin coated at 2 μg/well has a somewhat higher protein-binding capacity than that coated at 0.2 μg/well. This is consistent with our previous studies revealing that there Sugar array for glycosaminoglycan-protein interactions
Fig. 5. X-ray photoelectron spectroscopy (XPS) analysis of sulfated GAGs immobilized on microtiter plates. (A) and (C) Unfractionated heparin (UFH), C4S, DS, 2-O-deS, and N-deS/R
were incubated at either 0.2 (A) or 2.0 (C) μg/well with 100% allyl amine-coated microtiter plates and the amount of GAG bound to the surface was determined by XPS on the basis of the S2p sulfur (S) signal arising from sulfate groups; values are shown as mean S (atomic%) ± SEM (n = 3). (B) and (D) In order to determine the relative amount of bound GAGs associated with the plate surface the values in (A, C) were normalized relative to the approximate level of sulfation for each GAG, i.e., 2.5 sulfates per disaccharide in UFH, 1.5 in 2-O-deS and N-deS/R selectively desulfated heparins and 1 in chondroitin-4-sulfate and dermatan sulfate. These normalized values (B, D), i.e., for 0.2 and 2.0 μg/well, respectively, shown in arbitrary units, indicate that these sulfated GAGs are all immobilized on the 100% allyl amine surface in approximately equal amounts.
is not a direct correlation between the amount of immobilized heparin and its protein-binding capability (Robinson et al. 2008) . One possible explanation is that some minor components of the heterogeneous heparin preparation (e.g., highly charged species), which have a high-protein binding activity, become preferentially immobilized. In this regard, we found that there is a small (<20%) enrichment of sulfated species on allyl aminecoated electrospun meshes (as determined from disaccharide analysis of the bound and prebound GAG preparation) when using a highly heterogeneous HS preparation from porcine mucosa (Iduron, Manchester, UK) at 10 μg/mL coating concentration (i.e., equivalent to 2 μg/well in our assay), but that this increase is only statistically significant for 6-O-sulfation (Meade, Johnson, Holley, Downes, Whittle, Day and Merry, unpublished results). Therefore, there may be a small degree of preferential immobilization of certain highly sulfated species (e.g., particular 6-O-sulfated motifs) to allyl amine-coated microtiter plates when using heterogeneous heparin preparations, which could explain the higher binding of Link_TSG6 seen at 2 μg compared to 0.2 μg heparin/well (Figure 1) . However, given that these are relatively subtle effects and that the XPS experiments with different GAGs (Figure 5 ) indicate that binding is largely independent of the level of sulfation, in practical terms this does not appear to limit the use of this method for analysis of the GAG-binding specificity of a target protein.
Analysis of GAG-binding proteins using the sugar array
In order to test the utility of the sugar array, four nonrelated proteins were analyzed. Firstly, the bA-Link_TSG6 protein was tested ( Figure 7A ) and shown to give data consistent with the various "pilot" studies described above. Furthermore, these results are in agreement with the known GAG-binding properties of the TSG-6 protein (Parkar and Day 1997; Mahoney et al. 2004 Mahoney et al. , 2005 Milner et al. 2006) , i.e., it has specificity for the sulfated GAGs heparin, chondroitin-4-sulfate and dermatan sulfate, and the nonsulfated GAG hyaluronan. In this regard, it has been found that the TSG-6 Link module domain contains distinct hyaluronan and heparin-binding sites . The GAG-binding profile of the CCP6-8 "heparin"-binding domain from complement factor H obtained with the sugar array ( Figure 7B ) was in agreement with previous studies showing that factor H interacts with heparin and dermatan sulfate (Pangburn et al. 1991; Meri and Pangburn 1994; Saito et al. 2005; Clark et al. 2006; Prosser et al. 2007 ). To our knowledge the direct binding of factor H to chondroitin-4-sulfate and hyaluronan has not been examined previously; however, these GAGs have been concluded to have no effect on factor H function (Meri and Pangburn 1994) . Consistent with this, we saw no binding of the factor H CCP6-8 domain to hyaluronan at either coating concentration in the sugar array, and the low level of protein binding to chondroitin-4-sulfate was not dose dependent indicating that this is likely to be nonspecific; similarly a lack of binding was seen for these GAGs to immobilized CCP6-8 (Clark and Day, unpublished results). As described above the desulfation of heparin had a more dramatic effect on the interaction with Link_TSG6 compared to that with factor H. This is also clearly apparent from the sugar array profiles for these two proteins, indicating that TSG-6 and factor H display different structural requirements for heparin binding.
The GAG-binding profiles of two other (less well characterized) proteins were also investigated ( Figure 7C and D) , i.e., the N-terminal PF1 region of the elastic fiber protein fibrillin-1 (Marson et al. 2005 ) and the G1 domain of the proteoglycan versican (VG1) (Matsumoto et al. 2003; Seyfried et al. 2005) . Using the prototype sugar array, we identified the dose-dependent binding of PF1 to UFH and LMW heparin ( Figure 7C ), consistent with earlier studies demonstrating that PF1 contains a heparin-binding site . Interestingly, there was much weaker binding to 2-O-desulfated heparin (2-O-deS), whereas the interaction with N-deS/R was very similar to that with UFH. These data indicate that 2-O-sulfate groups are likely to have an important role in mediating the interaction of heparin with PF1, whilst N-sulfates are not significantly involved. In addition, we have found for the first time that fibrillin-1 interacts with dermatan sulfate, a characteristic that might correlate with the role of fibrillin-1 in maintaining the elastic integrity of the skin (Marson et al. 2005; Cain et al. 2008 ). However, the PF1 region of fibrillin-1 showed no binding to the related GAG chondroitin-4-sulfate or to hyaluronan, which is consistent with previous observations . Conversely, analysis of the GAG-binding properties of VG1 ( Figure 7D ) clearly showed that this domain does interact with the nonsulfated GAG hyaluronan. This is as expected given that versican is a well-established hyaluronan-binding protein, where the interaction site has been mapped to its N-terminal G1 domain (Matsumoto et al. 2003; Seyfried et al. 2005) . Whilst the protein ligands of versican (a chondroitin sulfate proteoglycan) have been described in detail (Kawashima et al. 2000; Wu et al. 2005; Kuznetsova et al. 2006) , its binding profile to sulfated GAGs has remained undefined. As can be seen from Figure 7D , in addition to hyaluronan, the VG1 domain interacts in a dosedependent manner with dermatan sulfate and also exhibits, apparently weaker, binding to heparin; however, no binding to chondroitin-4-sulfate was observed. Further research is now required to determine where the binding sites for these sulfated GAGs are located within the G1 domain and the functional relevance of these interactions.
Discussion
As described above, we have developed a sugar array that can be used to determine the GAG-binding profile of a target protein.
Given that microtiter plates coated with 100% allyl amine are commercially available (BD Biosciences Heparin Binding Plate, formerly termed EpranEx plates (Clark et al. 2006) ) and that all the GAGs we have used could be obtained from commercial suppliers, we believe that this simple methodology has wide utility. There is currently much interest in defining the carbohydratebinding properties of proteins, and there have been recent technological advances in this area (Fukui et al. 2002; Dendane et al. 2008; Tateno et al. 2008; Zhi et al. 2008 ). However, these more sophisticated technologies (e.g., using evanescent-field fluorescence-assisted detection of protein binding to covalently immobilized glycans (Tateno et al. 2008) or surface patterning of GAGs onto the inner wall of fused-silica capillary tubes (Dendane et al. 2008) ), or GAG attachment onto a gold-surfacebased platform (Zhi et al. 2008) , while of considerable potential value, are not, as yet, widely available, unlike the ELISA-like Sugar array for glycosaminoglycan-protein interactions Fig. 7 . GAG-binding profiles of four human proteins determined with the sugar array. Unfractionated heparin (UFH), LMW heparin (LMWH), chondroitin-4-sulfate (C4S), dermatan sulfate (DS), hyaluronan (HA), 2-O-desulfated heparin (2-O-deS), and N-desulfated/re-N-acetylated heparin (N-deS/R) were incubated with microtiter plates (coated with 100% allyl amine) at 0.2 μg/well (gray) and 2.0 μg/well (black). These immobilized GAGs were then used to determine the GAG-binding profiles of the proteins: (A) the Link module from human TSG-6 (TSG-6); (B) the Y384 variant of CCP6-8 from human factor H (Factor H); (C) the PF1 region from human fibrillin-1 (Fibrillin-1); and (D) the G1-domain from human versican (Versican). All values are plotted as mean absorbance (A 405 nm ) ± SEM (n = 6), corrected against blank wells (i.e., with no GAG); the data represent two independent experiments performed in triplicate each on a single microtiter plate. format that we have described. Importantly, our methodology, which involves the noncovalent association of GAGs with a plasma-polymerized surface, negates the need for labeling or chemical modification of the GAG (which in the other methods would have to be done for all GAG preparations (Fukui et al. 2002) ), underlining the simplicity and accessibility of this approach. In addition to the polysaccharides we chose to evaluate (which are representative of the different major types of GAG), we might have included other GAGs on our prototype sugar array, e.g., chondroitin-6-sulfate or keratan sulfate. It seems likely that these would have bound to the 100% allyl amine surface in a functional state given our results with the other GAGs analyzed, which have a wide variety of sulfation densities (i.e., from 0 to ∼2.5 sulfates per disaccharide) and saccharide chemistry/linkage. However, the TSG-6 Link module does not interact with chondroitin-6-sulfate (Parkar and Day 1997; Heng et al. 2008) and its binding to keratan sulfate has not been tested, making these GAGs unsuitable for use during the development stage of the technology. Previously, three different preparations of heparan sulfate (HSI, HSII, and heparan sulfate from bovine kidney), which have distinct sulfation patterns, have been used in binding assays on EpranEx plates , indicating that this family of GAGs could be included within this array format. Furthermore, we have shown that a wide range of selectively desulfated heparin preparations can be successfully analyzed on the allyl amine surface (Clark et al. 2006 ); see also Figure 4 . It is clear, therefore, that the sugar array methodology described here could be customized by the user to allow a wide variety of analyses to be undertaken. Thus, in summary, this unique tool could be of significant use as a simple, frontline technique for the determination of protein-GAG interactions.
Material and methods
GAGs and GAG-binding proteins LMW heparin and hyaluronan were obtained from Sigma Aldrich (Gillingham, UK; catalogue numbers H3400 and H1504, respectively) and chondroitin-4-sulfate was purchased from Merck Chemicals Ltd. (Nottingham, UK; catalogue number 230687). UFH corresponded to the 4th International Standard (IS) (Mulloy et al. 2000) and dermatan sulfate was purified from porcine mucosa and characterized by 1 H NMR spectroscopy as described previously (Pavão et al. 1995; Clark et al. 2006) .
were prepared from 2IS heparin (Mulloy et al. 2000) as before (Jaseja et al. 1989; Mulloy et al. 1994; Baumann et al. 1998; Ostrovsky et al. 2002) . Link_TSG6, the Y384 variant of complement factor H CCPs6-8, and the PF1 region of fibrillin-1 were made and biotinylated as we have described previously (Parkar and Day 1997; Cain et al. 2005; Clark et al. 2006) . 35 S-Labeled heparin (N-sulfonate) was supplied by GE Healthcare (Chalfont St Giles, UK). The G1 domain of human versican (VG1) was expressed in E. coli, purified to homogeneity (Fielder et al., in preparation) and then biotinylated as described before (Kuznetsova et al. 2006) .
Plasma polymerization
Different ratios of allyl amine (Sigma Aldrich) and octadiene (Sigma Aldrich) were plasma-deposited onto 96-well microtiter plates using the method described previously (Parry et al. 2006 ). This was done in a stainless steel reactor 60 cm in length and 50 cm in diameter, with an internal electrode; it was pumped to a base pressure of 10 −3 mbar by a two-stage rotary pump and liquid nitrogen cold trap, and the plasma was excited by a 13.56 MHz radiofrequency generator. The reactor was maintained at an operating pressure of 2 × 10 −2 mbar, while varying the partial pressure of the two monomers. Monomer ratios used were 100% allyl amine: 0% octadiene, 90% allyl amine: 10% octadiene, 80% allyl amine: 20% octadiene, 70% allyl amine: 30% octadiene, 60% allyl amine: 40% octadiene, 40% allyl amine: 60% octadiene, 20% allyl amine: 80% octadiene, and 0% allyl amine: 100% octadiene.
Microtiter plate binding assays
Plate assays were performed as we have reported previously (Mahoney et al. 2004 Clark et al. 2006; Robinson et al. 2008) . Briefly, GAGs were incubated with untreated microtiter plates, or identical plates coated with different monomer ratios of allyl amine:octadiene (see above), or BD heparin binding plates at 0-25 μg/mL (200 μL/well) in PBS for 18 h at room temperature in the dark. Plates were blocked with 1% (w/v) bovine serum albumin (Sigma Aldrich catalogue number A4503) in Standard Assay Buffer 6 (SAB6: 50 mM sodium acetate, 100 mM NaCl, 0.2% (v/v) Tween 20, pH 6) as described before . Wells were then incubated with a biotinylated protein (e.g., 2 pmol/well bA-Link_TSG6 in SAB6) for 4 h at room temperature, and the amount of bound protein, i.e., based on absorbance at 405 nm (A 405 nm ) after 10 min development, was detected as described in Robinson et al. (2008) .
In the case of the sugar array analysis, GAGs (UFH, LMW heparin, chondroitin-4-sulfate, dermatan sulfate, hyaluronan, 2-O-deS, and N-deS/R heparin) were incubated in PBS with 100% allyl amine plates at 0.2 or 2 μg/well and blocked as above. Incubation and detection of the biotinylated protein were performed as mentioned above except that factor H and VG1 were incubated (at 10 and 3 pmol/well, respectively), blocked, and washed in 20 mM HEPES, 130 mM NaCl, 0.05% Tween 20, pH 7.3, whilst fibrillin-1 PF1 (4 pmol/well) was incubated in 20 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl 2 , pH 7.8. The sugar arrays were developed for 10 min.
X-ray photoelectron spectroscopy (XPS)
For XPS analysis, GAGs (10 μg/mL in PBS, 200 μL/well) were incubated with microtiter plates coated with 100% allyl amine. Plates were then placed in the dark for 18 h at room temperature, after which surfaces were washed twice with PBS and left overnight to dry. Well bottoms were punched out from the plate for analysis. XPS data were acquired on a Kratos Axis UL-TRA "DLD" X-ray photoelectron spectrometer equipped with a monochromatic Al-Kα X-ray source and operating with a base pressure in the range 10 −8 mbar to 10 −10 mbar. Survey spectra (1200 eV-0 eV) were acquired at a pass energy of 160 eV and an X-ray power of 150 W. Sulfur S2p spectra were collected separately at a pass energy of 160 eV. High-resolution C1s spectra were acquired at a pass energy of 40 eV and an X-ray power of 150 W. The analysis area was approximately 300 μm × 700 μm. All samples were run as insulators. Subsequent processing was carried out using CasaXPS (www.casaxps.com). Spectral data were corrected for instrumental transmission and charge corrected to the C1s peak at 285.0 eV. Quantitative data were then obtained using theoretical Scofield photo-ionization cross sections. The level of adsorption of sulfated GAGs to the microtiter plate surface was determined by measuring the sulfur (S2p) signal.
Binding of
35 S-labeled heparin to allyl amine-coated plates 35 S-Labeled heparin (143 μCi/mg) and unlabeled LMW heparin (1:9 ratio) were added to 100% allyl amine plates at between 0.1 μg/well and 9.5 μg/well in PBS (200 μL/well) and incubated for 18 h at room temperature in the dark. The plates were then washed twice with PBS. Bound heparin was released by incubation of wells with 3 M NaCl (200 μL) for 1 h and the amount of radioactivity determined by scintillation counting where background from plates incubated with PBS alone was subtracted. 
